Critical appraisal:Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al 2015 2
From Cancer Guidelines Wiki
Risk of bias assessment: randomised controlled trial
Was the trial double-blinded?
- I am reasonably certain that the trial was double-blinded (eg identical placebo, active placebo, double-dummy, no revealing side-effects).
Was the treatment allocation schedule concealed?
- Adequately concealed (e.g. central randomisation, numbered or coded bottles, drugs prepared by pharmacy).
Were all randomised participants included in the analysis?
- No exclusions or survival analysis used with all subjects included (>95% follow-up for all groups).
The field below is not considered when calculating the risk of bias rating
Overall risk of bias
|Low risk of bias||Additional comments: Please replace this text and include any additional comments in regards to your risk of bias rating|
- Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015 Aug 1;386(9992):444-51 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26037941.
- Assigned to
- Topic area
- Clinical question
Section below only relevant for Cancer Council Project Officer